NDAORALTABLETPriority Review
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
EFFIENT (prasugrel hydrochloride) by Molecular Devices is p2y 12 class of adp receptors on platelets. Approved for thrombosis. First approved in 2009.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFFIENT (prasugrel hydrochloride) is an oral P2Y12 ADP receptor antagonist approved in 2009 for thrombosis prevention and COVID-19. It works by inhibiting platelet aggregation through irreversible binding to P2Y12 receptors, reducing the risk of thrombotic events in high-risk cardiovascular patients.
$39KPart D
LOE ApproachingDeclining
Minimal revenue generation with extremely low claim volume signals a mature, declining product with limited team expansion opportunities.
Mechanism of Action
P2Y 12 class of ADP receptors on platelets.
Indications (1)
Career Relevance
EFFIENT represents a declining-stage asset with minimal career growth potential; the zero linked job count and negligible revenue signal organizational deprioritization. Roles on this product are predominantly defensive, focusing on market maintenance and generic transition management rather than strategic expansion.
Brand Manager
Worked on EFFIENT at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.